The clue of genomic instability in breast cancerSeptember 07, 2004New research has shown, using human tissue biopsies - a hypothesis that until now could only be argued indirectly using cell cultures - that the significant increase in genomic "disorder" that is associated with breast cancer occurs in the transition between the typical hyperplasia and the in situ carcinoma, coinciding with a reduction to a critical minimum in the cell chromosome terminations (known as telomeres). This process of critical reduction, occurring due to the accumulation of cell divisions, causes problems in the cell division process, giving rise to cells with an abnormal genetic content. These cells are normally detected and eliminated from the organism thanks to a complex control and defence mechanism, but the activation of a protein known as telomerase is capable of short-circuiting these defence mechanisms and perpetuate these cells with abnormal genetic content, facilitating the development of the cancer. The research work was carried out in the prestigious Lawrence Berkeley National Laboratory of the US Department of Energy at Berkeley (California) in collaboration with the University of California in San Francisco. The contribution of the Spanish scientists Carlos Ortiz de Sol'łrzano and Enrique Garc'a Rodr'guez to the research was the development of programmes for the analysis of images from confocal 3D microscopy by which each cell can be observed separately and the amount of DNA in each cell nucleus determined. The number of de copies of genes involved in the development of the cancer and the number and length of the telomeres of these cells can be thus determined. This study would not have been possible without the 3D scientific visualisation programmes. The task group at the Lawrence Berkeley National Laboratory was directed by Dr. Carlos Ortiz de Sol'łrzano, who leads a microscopy and biomedical image analysis group. The work published by the latest number of Nature Genetics, one of the scientific journals with most impact in the field of biomedical research and the magazine of reference for genomic investigation, suggests that persons with benign tumours and who have a greater risk of developing cancer could be identified at an early stage by measuring telomerase activity; it opens the doors to the development of new therapeutic agents that selectively eliminate the tumorous cells, avoiding the reactivation of the telomerase enzyme in cells with an abnormal genetic content, or eliminate cells where the enzyme has been reactivated. Elhuyar Fundazioa |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||